Daewoong Pharmaceutical has unveiled its next growth strategy, the 'One Product, one Trillion Won Plan.' The goal is to achieve sales of over 1 trillion won (approx. $770 million) for three flagship…

Samsung Bioepis announced on the 23rd that it has received approval from the U.S. Food and Drug Administration (FDA) for 'Epysqli' (active ingredient: Eculizumab), a high-cost treatment for rare…

Celltrion announced on the 23rd that its third plant, located in Songdo, Incheon, is undergoing final validation before commencing commercial production. Validation is a critical procedure that…

Samsung Electronics has decided to effectively recall its new product, 'Buds 3 Pro', following criticisms of manufacturing and finishing defects. The company recently announced on its website, "We…

GC WellBeing Corporation Expected to See Stock Price Rise in H2 with Stable Sales Growth in Chinese Market Analysts predict that GC WellBeing Corporation will see a stable increase in sales and a…

The focus of global clinical trials is shifting from Europe to the United States and China, according to a recent market analysis. IQVIA, a global healthcare consulting firm, released a…

SK Biopharm is expected to continue its performance growth in the second half of the year, driven by the stable sales growth of its epilepsy treatment, Cenobamate (marketed in the U.S. as Xcopri).…

Analysts in the securities industry suggest paying attention to the clinical results to be released later this year by DongA ST's subsidiary, NeuroBo Pharmaceuticals (NeuroBo). On the 12th, Seo…

The dominance of the autoimmune disease treatment Humira (active ingredient: adalimumab), once the world's best-selling drug, is waning. Sandoz's biosimilar Hyrimoz has rapidly gained market share,…

“The GLP-1 obesity treatment market is expected to grow to 100 trillion won( approximately 77 billion dollars) by 2030. Including metabolic-associated steatohepatitis (MASH),…